Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sweat test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    211 result(s) found for: Sweat test. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-000922-46 Sponsor Protocol Number: GPBK-08/2018 Start Date*: 2023-01-27
    Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel
    Full Title: An Open-Label, Uncontrolled, Multicenter Study to Evaluate the Safety, Local Tolerability, Systemic Exposure, and Efficacy of 1% GPB Cream in Adolescents With Severe Primary Axillary Hyperhidrosis ...
    Medical condition: Severe primary axillary hyperhidrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002068-34 Sponsor Protocol Number: 2013-RC-09 Start Date*: 2015-06-10
    Sponsor Name:DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES
    Full Title: Prospective Multicentric Open Randomised Controlled Trial comparing Topical Aluminium Chloride to Onabotulinumtoxin A Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)
    Medical condition: Residual Limb Hyperhidrosis is the investigated medical condition.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011042-26 Sponsor Protocol Number: V 1.01 Start Date*: 2011-09-08
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Neurologie
    Full Title: Botulinumtoxin type B for plantar hyperhidrosis: a randomised controlled trial
    Medical condition: plantar hyperhidrosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001258-82 Sponsor Protocol Number: CFTRcysta1 Start Date*: 2013-09-12
    Sponsor Name:European Institute for Cystic Fibrosis Research (IERFC)
    Full Title: A phase II pilot clinical study of experimental research to evaluate the functional rescue of CFTR protein through proteostasis regulators
    Medical condition: Cystic fibrosis patients with F508del-CFTR in homozygous or compound heterozygous with Class I or II mutations
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007055-13 Sponsor Protocol Number: CTU 043C Start Date*: 2009-07-17
    Sponsor Name:RIEMSER Arzneimittel AG
    Full Title: DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PROSPECTIVE MULTI-CENTRE PHASE III TRIAL TO ASSESS THE EFFICACY AND SAFETY OF METHANTHELINIUM BROMIDE (VAGANTIN®) IN THE TREATMENT OF FOCAL PALMAR-AXILL...
    Medical condition: Treatment of patients with axillary and palmar hyperhidrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020413-90 Sponsor Protocol Number: VX09-809-102 Start Date*: 2011-01-06
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and L...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002052-27 Sponsor Protocol Number: DRM04-HH04 Start Date*: 2015-10-14
    Sponsor Name:Dermira, Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED EFFICACY AND SAFETY STUDY OF DRM04 IN SUBJECTS WITH AXILLARY HYPERHIDROSIS
    Medical condition: Primary axillary hyperhidrosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003585-11 Sponsor Protocol Number: VX16-659-101 Start Date*: 2017-09-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004534-28 Sponsor Protocol Number: Hyp1-18/2016 Start Date*: 2018-08-09
    Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel
    Full Title: Combined Randomized, Double-Blind, Dose-Confirming Phase 3a Study in Parallel Design to Assess the Efficacy and Safety of Topical 4-Week Treatment With 1% GPB Cream vs Placebo and Open-Label Phase...
    Medical condition: Severe primary axillary hyperhidrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) HU (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002532-23 Sponsor Protocol Number: ER004-CLIN01/F60082AI201 Start Date*: 2021-10-25
    Sponsor Name:EspeRare Foundation [...]
    1. EspeRare Foundation
    2. Pierre Fabre Médicament
    Full Title: A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-link...
    Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10072592 Hypohidrotic ectodermal dysplasia LLT
    Population Age: In utero, Under 18 Gender: Male
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004293-10 Sponsor Protocol Number: REH-TOX-2013-01 Start Date*: 2014-06-03
    Sponsor Name:Hospital Universitari de Tarragona Joan XXIII
    Full Title: Efficacy of treatment by iontophoresis of botulinum toxin type A free from complexing proteins for stump hyperhidrosis
    Medical condition: Stump hyperhidrosis in lower limb amputees
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003970-28 Sponsor Protocol Number: VX18-561-101 Start Date*: 2019-06-18
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001796-31 Sponsor Protocol Number: ACR/GLYCAD/1375 Start Date*: 2014-10-30
    Sponsor Name:L’OREAL SA
    Full Title: A monocenter, double-blind, randomized study to assess the kinetic of antiperspirant efficacy of Glycopyrrolate 0.2% and 0.02% versus placebo during 4 days of topical applications on axilla of heal...
    Medical condition: The study will be performed in healthy volunteers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003319-21 Sponsor Protocol Number: PTI-808-01 Start Date*: 2018-07-20
    Sponsor Name:Proteostasis Therapeutics, Inc.
    Full Title: A Phase 1 / 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults with Cystic Fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001997-16 Sponsor Protocol Number: VX15-770-124 Start Date*: Information not available in EudraCT
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Init...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003561-17 Sponsor Protocol Number: ECP-002 Start Date*: 2013-08-09
    Sponsor Name:Edimer Pharmaceuticals, Inc.
    Full Title: A Phase 2 open-label, dose-escalation study to evaluate the safety, pharmacokinetics, immunogeniticy and pharmacodynamics/efficacy of EDI200, an EDA-A1 replacement protein, administered to male inf...
    Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by inherited defects in the ectodysplasin (EDA) gene that disrupt synthesis and/or function of the primary translational product EDA-A1....
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10072592 Hypohidrotic ectodermal dysplasia LLT
    Population Age: Newborns, Under 18 Gender: Male
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001259-29 Sponsor Protocol Number: UoL001306 Start Date*: 2019-03-12
    Sponsor Name:University of LIverpool
    Full Title: A PHASE 1B/2A STUDY TO ASSESS THE TOLERABILITY AND ADVERSE EFFECT PROFILE OF CYSTEAMINE (CYSTAGON) IN ADULTS AND CHILDREN WITH HOMOZYGOUS ΔF508 CYSTIC FIBROSIS, IN PATIENTS TAKING EPIGALLOCATECHIN-...
    Medical condition: DeltaF508 Homozygous Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000797-11 Sponsor Protocol Number: VX16-445-001 Start Date*: 2017-10-06
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects with Cystic Fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002181-42 Sponsor Protocol Number: GLPG2737-CL-202 Start Date*: 2017-10-27
    Sponsor Name:Galapagos NV
    Full Title: A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2737 in Orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003761-99 Sponsor Protocol Number: VX16-809-121 Start Date*: 2018-06-27
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: An Exploratory Phase 2, 2-part, Randomized, Double blind, Placebo controlled Study With a Long term, Open label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjec...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 04:55:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA